Evidence before this study
RVF, RIFT VALLEY FEVER
Both the WHO and African Union have identified vaccine development for RVF in humans as an urgent priority owing to its potential to cause a public health emergency with devastating health consequences and major economic impacts. The goal of RVF vaccinology has been to design vaccines that are safe and highly immunogenic for neutralizing antibody (nAb) - which are associated with protection - in addition to other optimal product characteristics defined by the WHO. We conducted a search for RVF vaccine trials on ClinicalTrials.gov (using: (Rift Valley Fever) AND (vaccine) with no date restrictions). Two candidate vaccines, the inactivated TSI-GSD-200 vaccine, and the live-attenuated MP-12 vaccine, have previously been evaluated in humans and shown to safely elicit nAb. TSI-GSD-200 has been registered on ClinicalTrials.gov as currently recruiting for phase 2 trial but there have been no further updates on the clinical development of MP-12 for human use since completion of a phase 2 trial in 2009. ChAdOx1 RVF, which is described in this manuscript is also listed as undergoing a separate phase 1b trial in Uganda (registration number:NCT04672824). As with TSI-GSD-200 and MP-12, further evaluation of ChAdOx1 RVF in humans follows demonstration of safety, immunogenicity and efficacy against RVF in livestock.